TIGIT, or T-cell immunoreceptor with immunoglobulin and ITIM domain, is an inhibitory immune checkpoint receptor that has recently gained attention for its role in modulating immune responses, especially within the tumor microenvironment (TME). Targeting TIGIT has emerged as a promising therapeutic strategy in cancer immunotherapy due to its effects on T-cells, NK cells, and regulatory […]
Interferon Gamma Receptor 1 (IFNγR1) is a critical component of the immune system’s response to pathogens and cancer. This protein is essential for recognizing and responding to interferon-gamma (IFNγ), a cytokine with potent immunomodulatory and anti-microbial effects. The IFNγR1 subunit, together with IFNγR2, forms the interferon-gamma receptor complex, which plays a role in activating immune […]
CXCR4, or C-X-C Chemokine Receptor Type 4, is a highly conserved G-protein-coupled receptor (GPCR) primarily involved in cellular migration, immune responses, and tissue repair. CXCR4 is one of the most studied chemokine receptors due to its role in various diseases, including cancer, liver disease, and HIV infection.1, 2 CXCR4’s primary ligand, CXCL12 (also known as […]
Nature holds the blueprint for many of science’s most promising therapeutic solutions. At Conigen, we’ve harnessed these native designs to introduce our latest Claudin protein family (Claudin 3, Claudin 6, Claudin 9) of membrane proteins displayed on nanoparticles, and developed to reflect bioactive native conformations that drive innovation in cancer therapies and vaccine research. By […]
